- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
New Pancreatic Cancer Drugs' Revenue Potential "Limited"
The pancreatic cancer market is set to climb from $855.8 million in 2012 to approximately $1.21 billion by 2019 (a CAGR of 5.1%), says a report from GBI Research.
The pancreatic cancer market is set to climb from $855.8 million in 2012 to approximately $1.21 billion by 2019 (a CAGR of 5.1%), says a report from GBI Research. The growth will be fueled by increasing global prevalence of the disease, coupled with the launch at least three new drugs: the recently approved Abraxane (Celgene), and the upcoming TH-302 from Threshold and Merrimack’s MM-398.
However, each of these drugs’ market penetration and subsequent impact on revenues is expected to be limited.
Katie Noon, an analyst for GBI Research, said: ““Potential targeted therapies that have previously been analyzed in clinical trials include vascular endothelial growth factor receptors and epidermal growth factor receptors, but these have had limited success. As a heterogenous disease, it is likely that a combination of targeted therapies will have to be employed to develop an effective treatment for pancreatic cancer.”
While numerous novel agents for targeted therapies are currently being analyzed in the disease’s developmental pipeline, many of these have not been investigated in a clinical setting before now, according to GBI Research.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
